Clinical Trial Update: Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating high-dose aflibercept injected into the eye for neovascular age-related macular degeneration has completed, with trial results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Neovascular Age-Related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2023-09-06